CSL – Citi rates the stock as Upgrade to Buy from Neutral

A brave team of healthcare analysts at Citi has upgraded CSL to Buy from Neutral if only because the share price continues to weaken. Citi has kept the $332 price target intact, while forecasting double-digit percentages growth in EPS for each of the following three years.

Moreover, Citi analysts believe risk to earnings in the medium-term remains to the upside because CSL continues to increase market share due to its superior plasma collection position.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $332.00.Current Price is $280.51. Difference: $51.49 – (brackets indicate current price is over target). If CSL meets the Citi target it will return approximately 16% (excluding dividends, fees and charges – negative figures indicate an expected loss).

 

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →